Events

Through a solid and well-structured strategy, GWO XI Stem Cell successfully exceeded 100 patent applications in 2023, with patents spanning the upstream, midstream, and downstream segments of the cell therapy industry, highlighting the depth of GWO XI’s technological expertise. In addition, GWO XI continues to translate its technology from basic science to clinical applications. Currently, four stem cell-based therapeutics have entered clinical trials. With a broad product pipeline and a strong technological foundation, GWO XI moves forward with confidence toward the future.

 

According to the Industry Value Chain Information Platform, the cell therapy industry spans upstream stem cell collection and storage, midstream stem cell development, and downstream clinical trials, transplantation technologies, and disease treatments. GWO XI holds key patents across the entire cell therapy value chain, safeguarding the overall manufacturing process. In the cell therapy industry, there is a saying: “the process is the product,” meaning that the process technology significantly affects the quality of cell-based therapeutics. Moreover, in the new drug industry, intellectual property (IP) is of critical importance, underscoring the significance of GWO XI’s strategic patent portfolio. Through a steady and long-term approach, GWO XI aims to become a globally influential cell therapy company in the future.